Health Trials

PET-MF

1

Review clinical trials related to PET-MF. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ajax Therapeutics, Inc.Updated: May 12, 2026Locations: 21
Eligibility criteria

18 years of age or older. [+12]

Prior splenectomy. [+11]

Read more